Cargando…

Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea

This study aims to compare the prevalence and seriousness of adverse events (AEs) among sedatives used in critically ill patients or patients undergoing invasive procedures and to identify factors associated with serious AEs. Retrospective cross-sectional analysis of sedative-related AEs voluntarily...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yeo-Jin, Yang, Seung-Won, Kwack, Won-Gun, Lee, Jun-Kyu, Lee, Tae-Hee, Jang, Jae-Yong, Chung, Eun-Kyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399659/
https://www.ncbi.nlm.nih.gov/pubmed/34451882
http://dx.doi.org/10.3390/ph14080783
_version_ 1783745131043618816
author Choi, Yeo-Jin
Yang, Seung-Won
Kwack, Won-Gun
Lee, Jun-Kyu
Lee, Tae-Hee
Jang, Jae-Yong
Chung, Eun-Kyoung
author_facet Choi, Yeo-Jin
Yang, Seung-Won
Kwack, Won-Gun
Lee, Jun-Kyu
Lee, Tae-Hee
Jang, Jae-Yong
Chung, Eun-Kyoung
author_sort Choi, Yeo-Jin
collection PubMed
description This study aims to compare the prevalence and seriousness of adverse events (AEs) among sedatives used in critically ill patients or patients undergoing invasive procedures and to identify factors associated with serious AEs. Retrospective cross-sectional analysis of sedative-related AEs voluntarily reported to the Korea Adverse Event Reporting System from 2008 to 2017 was performed. All AEs were grouped using preferred terms and System Organ Classes per the World Health Organization—Adverse Reaction Terminology. Logistic regression was performed to identify factors associated with serious events. Among 95,188 AEs, including 3132 (3.3%) serious events, the most common etiologic sedative was fentanyl (58.8%), followed by pethidine (25.9%). Gastrointestinal disorders (54.2%) were the most frequent AEs. The most common serious AE was heart rate/rhythm disorders (33.1%). Serious AEs were significantly associated with male sex; pediatrics; etiologic sedative with etomidate at the highest risk, followed by dexmedetomidine, ketamine, and propofol; polypharmacy; combined sedative use; and concurrent use of corticosteroids, aspirin, neuromuscular blockers, and antihistamines (reporting odds ratio > 1, p < 0.001 for all). Sedative-induced AEs are most frequently reported with fentanyl, primarily manifesting as gastrointestinal disorders. Etomidate is associated with the highest risk of serious AEs, with the most common serious events being heart rate/rhythm disorders.
format Online
Article
Text
id pubmed-8399659
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83996592021-08-29 Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea Choi, Yeo-Jin Yang, Seung-Won Kwack, Won-Gun Lee, Jun-Kyu Lee, Tae-Hee Jang, Jae-Yong Chung, Eun-Kyoung Pharmaceuticals (Basel) Article This study aims to compare the prevalence and seriousness of adverse events (AEs) among sedatives used in critically ill patients or patients undergoing invasive procedures and to identify factors associated with serious AEs. Retrospective cross-sectional analysis of sedative-related AEs voluntarily reported to the Korea Adverse Event Reporting System from 2008 to 2017 was performed. All AEs were grouped using preferred terms and System Organ Classes per the World Health Organization—Adverse Reaction Terminology. Logistic regression was performed to identify factors associated with serious events. Among 95,188 AEs, including 3132 (3.3%) serious events, the most common etiologic sedative was fentanyl (58.8%), followed by pethidine (25.9%). Gastrointestinal disorders (54.2%) were the most frequent AEs. The most common serious AE was heart rate/rhythm disorders (33.1%). Serious AEs were significantly associated with male sex; pediatrics; etiologic sedative with etomidate at the highest risk, followed by dexmedetomidine, ketamine, and propofol; polypharmacy; combined sedative use; and concurrent use of corticosteroids, aspirin, neuromuscular blockers, and antihistamines (reporting odds ratio > 1, p < 0.001 for all). Sedative-induced AEs are most frequently reported with fentanyl, primarily manifesting as gastrointestinal disorders. Etomidate is associated with the highest risk of serious AEs, with the most common serious events being heart rate/rhythm disorders. MDPI 2021-08-09 /pmc/articles/PMC8399659/ /pubmed/34451882 http://dx.doi.org/10.3390/ph14080783 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Choi, Yeo-Jin
Yang, Seung-Won
Kwack, Won-Gun
Lee, Jun-Kyu
Lee, Tae-Hee
Jang, Jae-Yong
Chung, Eun-Kyoung
Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea
title Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea
title_full Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea
title_fullStr Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea
title_full_unstemmed Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea
title_short Comparative Safety Profiles of Sedatives Commonly Used in Clinical Practice: A 10-Year Nationwide Pharmacovigilance Study in Korea
title_sort comparative safety profiles of sedatives commonly used in clinical practice: a 10-year nationwide pharmacovigilance study in korea
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399659/
https://www.ncbi.nlm.nih.gov/pubmed/34451882
http://dx.doi.org/10.3390/ph14080783
work_keys_str_mv AT choiyeojin comparativesafetyprofilesofsedativescommonlyusedinclinicalpracticea10yearnationwidepharmacovigilancestudyinkorea
AT yangseungwon comparativesafetyprofilesofsedativescommonlyusedinclinicalpracticea10yearnationwidepharmacovigilancestudyinkorea
AT kwackwongun comparativesafetyprofilesofsedativescommonlyusedinclinicalpracticea10yearnationwidepharmacovigilancestudyinkorea
AT leejunkyu comparativesafetyprofilesofsedativescommonlyusedinclinicalpracticea10yearnationwidepharmacovigilancestudyinkorea
AT leetaehee comparativesafetyprofilesofsedativescommonlyusedinclinicalpracticea10yearnationwidepharmacovigilancestudyinkorea
AT jangjaeyong comparativesafetyprofilesofsedativescommonlyusedinclinicalpracticea10yearnationwidepharmacovigilancestudyinkorea
AT chungeunkyoung comparativesafetyprofilesofsedativescommonlyusedinclinicalpracticea10yearnationwidepharmacovigilancestudyinkorea